Ustekinumab in the therapy of chronic plaque psoriasis

Biologics: Targets and Therapy

Volumn 3, Issue , 2009, Pages 159-168

  O'Neill, Jenna L ^a   Kalb, Robert E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Plaque; Psoriasis; Ustekinumab

Indexed keywords

EID: 70449712998     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S3498     Document Type: Review

References (87)

1. Watson W, Cann HM, Farber EM, Nall ML. The genetics of psoriasis. Arch Dermatol. 1972;105:197-207.
2. Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol. 1974;109:207-211.
3. Owen CM, Chalmers RJ, O'Sullivan T, Griffiths CE. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database Syst Rev. 2000;2:CD001976.
4. Mueller W, Herrmann B. Cyclosporine A for psoriasis. N Engl J Med. 1979;301:555.
5. Gardembas-Pain M, Ifrah N, Foussard C, Boasson M, Saint Andre JP, Verret JL. Psoriasis after allogenic bone marrow transplantation. Arch Dermatol. 1990;126:1523.
6. Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med. 2004;199:731-736.
7. Austin LM, Ozawa M, Kikuchi T, et al. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type I cytokines, IFN-γ, IL-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a Type I differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol. 1999;113:752-759.
8. Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352: 1899-1912.
9. Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB. Efalizumab: results of a 3-year continuous dosing study for the longterm control of psoriasis. Br J Dermatol. 2008;158:1107-1116.
10. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143:719-26.
11. Bos JD, Hulsebosch HJ, Krieg SR, Bakker PM, Cormane RH. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res. 1983;275:181-189.
12. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145-173.
13. Braun-Falco O, Schmoeckel C. The dermal inflammatory reaction in initial psoriatic lesions. Arch Dermatol Res. 1977;258:9-16.
14. Krueger JG. Pathogenic interactions of keratinocytes and T lymphocytes in psoriasis. In: Roenigk HH, Maibach HI, editors. Psoriasis. New York: Marcel Dekker; 1998. p. 315-327.
15. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996;184(2)747-752.
16. Peng X, Kasran A, Warmerdam PA, de Boer M, Ceuppens JL. Accessory signaling by CD40 for T cell activation: induction of Th1 and Th2 cytokines and synergy with interleukin-12 for interferon-gamma production. Eur J Immunol. 1996;26:1621-1627.
17. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factoralpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol. 1999;113:752-759.
18. Yawalkar N, Karlen S, Hunger R, Brand CU, Braathen LR. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol. 1998;111:1053-1057.
19. Trepicchio WL, Ozawa M, Walters IB, et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest. 1999;104:1527-1537.
20. Germann T, Gately MK, Schoenhaut DS, et al. Interleukin-12/T cell stimulating factor, a cytokine with multiple effects of T helper (Th1) but not on Th2 cells. Eur J Immunol. 1993;23:1762-1770.
21. Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. JAAD. 2007;57(6):1059-1068.
22. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol. 1999;135:1104-1110.
23. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278: 1910-1914.
24. Park H, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nature Immunol. 2005;6: 1133-1141.
25. Gately MK, Desai BB, Wolitzky AB, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol. 1991;147(3):874-882.
26. Babik JM, Adams E, Tone Y, Fairchild PJ, Tone M, Waldmann H. Expression of murine IL-12 is regulated by translational control of the p35 subunit. J Immunol. 1999;162(7): 4069-4078.
27. Watford WT, Moriguchi M, Morinobu A, O'Shea JJ. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokin Growth Factor Rev. 2003;14:361-368.
28. Micallef MJ, Ohtsuki T, Kohno K, et al. Interferon-γ-inducing factor enhances T helper I cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-γproduction. Eur J Immunol. 1996;26(7): 1647-1651.
29. Lauwerys BR, Renauld JC, Houssiau FA. Synergistic proliferation and activation of natural killer cells by interleukin-12 and interleukin-18. Cytokine. 1999;11(11):822-830.
30. Gran B, Zhang GX, Rostami A. Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination. Crit Rev Immunol. 2004;24:111-128.
31. Ma X, Trinchieri G. Regulation of interleukin-12 production in antigenproducing cells. Adv Immunol. 2001;79:55-92.
32. Ma X, et al. The interleukin-12 p40 gene promoter is primed by interferon-γin monocytic cells. J Exp Med. 1996;183(1):147-157.
33. Chu CQ, Wittmer S, Dalton DK. Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J Exp Med. 2000;192:123-128.
34. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715-725.
35. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL23-IL17 immune pathway. Trends Immunol. 2006;27(1):17-23.
36. Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev. 2004;202:96-105.
37. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8(9):950-957.
38. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203:2577-2587.
39. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199:125-130.
40. Presky DH, Yang H, Minetti LJ, et al. A functional interleukin 12 receptor complex is composed of two ββtype cytokine receptor subunits. Proc Natl Acad Sci USA. 1996;93: 14002-14007.
41. Lighvani AA, Frucht DM, Jankovic D, et al. T-bet is rapidly induced by interferon-γγin lymphoid and myeloid cells. Proc Natl Acad Sci U S A. 2001;98(26): 15137-15142.
42. Afkarian M, Sedy JR, Yang J, et al. T-bet is a STAT1-induced regulator of IL-12 receptor expression in naïve CD4eeT cells. Nat Immunol. 2002;3(6):549-557.
43. Grohmann U, Frucht DM, Jankovic D, et al. IL-12 acts directly on DC to promote nuclear localization of NF-κββand primes DC for IL-12 production. Immunity. 1998;9:315-323.
44. Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002:168(11):5699-5708.
45. McGovern D, Powrie F. The IL23 axis plays a key role in the pathogenesis of IBD. Gut. 2007;56(10):133-136.
46. Belladonna ML, Renauld JC, Bianchi R, et al. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J Immunol. 2002;168:5448-5454.
47. Magram J, Connaughton SE, Warrier RR, et al. IL-12-deficient mice are defective in IFN-γγproduction and type I cytokine responses. Immunity. 1996;4(5):471-481.
48. Wu C, Ferrante J, Gately MK, Magram J. Characterization of IL-12 receptorβ1 chain (IL-12Rβ1)-deficient mice: IL-12Rβ1 is an essential component of the functional mouse IL-12 receptor. J Immunol. 1997;159(4):1658-1665.
49. Camoglio L, Juffermans NP, Peppelenbosch M, et al. Contrasting roles of IL-12p40 and IL-12p35 in the development of hapten-induced colitis. Eur J Immunol. 2002;32(1):261-269.
50. Lieberman LA, Cardillo F, Owyang AM, et al. IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12. J Immunol. 2004;173(3):1887-1893.
51. Becher B, Durell BG, Noelle RJ. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest. 2002;110:493-497.
52. Lee E, Trepicchio WL, Oestericher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199:125-130.
53. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-γγsynergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol. 1998;111:645-649.
54. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol. 2007;19:281-286.
55. Wynn TA. T(H)-17: a giant step from T(H)1 and T(H)2 [comment]. Nat Immunol. 2005;6:1069-1070.
56. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are co-expressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006;203:2271-2279.
57. Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Imunnol. 2006;36:1309-1323.
58. Kikly K, Liu L, Na S, Sedgwick JD. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol. 2006;18(6):670-675.
59. Asarch A, Barak O, Loo D, Gottlieb A. Th17 cells: a new paradigm for cutaneous inflammation. J Dermatolog Treat. 2008;19:259-266.
60. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445:648-651.
61. Kreymborg K, Böhlmann U, Becher B. IL-23: changing the verdict on IL-12 function in inflammation and autoimmunity. Expert Opin Ther Targets. 2005;9(6):1123-1136.
62. Brok HP, van Meurs M, Blezer E, et al. Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol. 2002;169: 6554-6563.
63. Kasper LH, Everitt D, Leist T, et al. Safety, pharmacokinetic, and biological response profile of an IL-12p40 antagonist in MS: A phase I clinical trial. Proc Congress Eur Committee Treatment Res Multiple Sclerosis. 2004;107.
64. Leonard JP, Waldburger KE, Goldman SJ. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med. 1995;181(1):381-386.
65. Malfait AM, Butler DM, Presky DH, Maini RN, Brennan FM, Feldmann M. Blockade of IL-12 during the induction of collageninduced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol. 1998;111(2):377-383.
66. Brok HP, van Meurs M, Blezer E, et al. Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol. 2002;169(11): 6554-6563.
67. Hong K, Chu A, Ludviksson BR, Berg EL, Ehrhardt RO. IL-12, independently of IFN-γ, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J Immunol. 1999;162:7480-7491.
68. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomized, dose-ranging study. Lancet Neurol. 2008;7(9):796-804.
69. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate to severe Crohn's disease. Gastroenterology. 2008;135(4):1130-1141.
70. Kauffman CL, Aria N, Toichi E, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol. 2004;123:1037-1044.
71. Gottlieb AB, Cooper KD, McCormick TS, et al. A phase 1, doubleblind, placebo-controlled study evaluating single subcutaneous administration of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin. 2007;23:1081-1092.
72. Toichi E, Torres G, McCormick TS, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL12/IL23 in psoriasis. J Immunol. 2006;177(7):4917-4926.
73. Toichi E, McCormick TS, Kaufmann CL, et al. Quantitation of cutaneous cytokine mRNA levels following anti-IL-12 psoriasis therapy: identification of a psoriasis subset. J Invest Dermatol. 2003;121:1249.
74. Krueger GC, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356:580-592.
75. Leonardi C, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX1). Lancet. 2008;371:1665-1674.
76. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX1). Lancet. 2008;371:1675-1684.
77. Niemann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829-835.
78. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002;13:155-168.
79. Overwijk WW, de Visser KE, Tirion FH, et al. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol. 2006;176:5213-5222.
80. Tan ZY, Bealgey KW, Fang Y, Gong YM, Bao S. Interleukin-23: immunological roles and clinical implications. Int J Biochem Cell Biol. 2008;doi:10.1016/j.biocel. 2008.04.027.
81. Ghiladri N, Klajavin N, Chen Q, Lucas S, Gurney AL, Sauvage FJ. Compromised humoral and delayed-type hypersensitivity responses in IL-23 deficient mice. J Immunol. 2004;172(5):2827-2833.
82. de Jong R, Altare F, Haagen IA, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science. 1998;280(5368):1435-1438.
83. Doffinger R, Dupuis S, Picard C, et al. Inherited disorders of IL-12 and IFN-γ-mediated immunity: a molecular genetics update. Mol Immunol. 2002;38(12-13):903-909.
84. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-2022.
85. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. An international, randomized, double-blind, placebocontrolled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719-727.
86. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004-2013.
87. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts A. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA. 2008;300(16): 1887-1896.